Research and clinical trials

This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...

Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with...

This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...

This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...

This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...

The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...

Early-stage work on a new bispecific antibody could point to a different immune-regulatory approach for treating inflammatory bowel disease. Patients and clinicians watching IBD drug development may find the mechanism...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.

Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...

This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate...

Researchers and companies continue exploring new immune-targeted therapies for IBD. A new DR3-targeted antibody could become a future treatment direction if clinical studies show benefit and safety. This announcement...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.

This article describes implantable vagus nerve stimulators being studied as a way to reduce inflammation in autoimmune diseases, including Crohn’s disease. If effective, these devices could offer a non-drug option or...

Fundraising events like this support research and patient services for people with Crohn’s disease and ulcerative colitis. They also raise public awareness about IBD, which can reduce stigma and increase community...

New FDA approval adds another IL‑23p19 biologic option for moderate‑to‑severe Crohn’s disease and highlights two‑year efficacy data, which may affect treatment choices and future pediatric availability.

Based on the title and source metadata, this appears to be a biomarker study related to Inflammatory bowel disease, Colorectal Cancer Risk, and Research and clinical trials. The original article is from msn.com.

A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...

Based on the title and source metadata, this appears to be a market or business news related to Inflammatory bowel disease and Access, cost, and policy. The original article is from menafn.com.

The study identifies a specific bacterial protein region (flagellin epitope) that many Crohn’s patients make antibodies to, which could help diagnose disease and predict who may develop complications.

Diet is a modifiable factor that may influence inflammation and the gut microbiome. If the Mediterranean diet is linked with lower disease activity and inflammatory markers in newly diagnosed Crohn’s disease, patients...

Based on the title and source metadata, this appears to be a clinical study related to Research and clinical trials. The original article is from msn.com.

Cure8 could only read part of this source from healthcentral.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis.

Fundraising events support IBD research, programs and patient services. Money raised can contribute to work on personalized treatments and diagnostic tools that might benefit people with Crohn’s disease or ulcerative...

A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from jewishpress.com.

Cure8 could only read part of this source from morningstar.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...

The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency....

Cure8 could only read part of this source from whatech.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Inflammatory bowel disease, and Biomarker. The original article is from firstwordpharma.com.

The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...

This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...

This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...

Based on the title and source metadata, this appears to be a market or business news related to Inflammatory bowel disease, Crohn's disease, and Research and clinical trials. The original article is from...

A pipeline overview can indicate which new drugs and trials might affect future treatment options for Crohn’s disease. Patients on biologics or those with treatment-refractory disease may see new options under study that...

The event raised funds for the Crohn’s & Colitis Foundation, which supports IBD research, education, and patient care. Community fundraising events can expand local support networks and resources for people living with...

This study suggests a Crohn's genetic risk factor can change pregnancy-related gut microbiome shifts and increase inflammatory signals in mice — which could help researchers look for microbial biomarkers that predict...

If you have Crohn’s disease, this study suggests following a Mediterranean-style diet may be linked with lower inflammation and a gentler disease course, and it could positively change the gut microbiome and metabolites.

Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Inflammatory bowel disease, and Biomarker. The original article is from generalsurgerynews.com.

This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...

A study aiming to identify who is likely to develop Crohn’s disease and to test preventing it could eventually allow truly early treatment before symptoms begin. If successful, validated biomarkers and a risk score could...

Cure8 could only read part of this source from patientcareonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker.

Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.

People with celiac disease may have higher risks for several digestive cancers and for inflammatory bowel diseases (Crohn’s and UC) according to this large French cohort study. Knowing these associations can help...

If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...

This project aims to detect Crohn’s before symptoms appear and test preventive treatment—research that could change diagnosis and care for people with family risk. Successful biomarkers could allow earlier monitoring or...